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Abstract. AlthoughPlasmodium falciparum continues to be themain target formalaria elimination, otherPlasmodium
species persist in Africa. Their clinical diagnosis is uncommon, whereas rapid diagnostic tests (RDTs), the most widely
usedmalaria diagnostic tools, are only able to distinguish betweenP. falciparum and non-falciparum species, the latter as
“pan-species.” Blood samples from health facilities were collected in southern Nigeria (Lagos and Calabar) in 2017
(October–December) and Calabar only in 2018 (October–November), and analyzed by several methods, namely, mi-
croscopy, quantitative real-time PCR (qPCR), and peptide serology targeting candidate antigens (Plasmodium malariae
apical membrane antigen, P. malariae lactose dehydrogenase, and P.malariae circumsporozoite surface protein). Both
microscopy and qPCR diagnostic approaches detected comparable proportions (∼80%) of all RDT-positive samples
infected with the dominant P. falciparum malaria parasite. However, higher proportions of non-falciparum species were
detectedbyqPCR thanmicroscopy, 10%against 3% infections forP.malariaeand3%against 0% forPlasmodiumovale,
respectively.NoPlasmodiumvivax infectionwasdetected. Infection rates forP.malariae variedbetweenage-groups,with
the highest rates in individuals aged > 5 years. Plasmodium malariae–specific seroprevalence rates fluctuated in those
aged < 10 years but generally reached the peak around 20 years of age for all peptides. The heterogeneity and rates of
these non-falciparum species call for increased specific diagnosis and targeting by elimination strategies.
INTRODUCTION
Current global efforts toward malaria elimination target the
dominant malaria parasites, Plasmodium falciparum and
Plasmodium vivax.1 However, there are three other malaria
species infecting humans, with Plasmodium malariae being
the most common worldwide, including sub-Saharan Africa
(sSA).2 Plasmodium malariae causes the so-called quartan
malaria, as the onset of fever occurs in an interval of 3–4 days,
because of its 72-hour blood stage life cycle.3,4 Compared
with falciparum malaria, it is a relatively benign infection,
possibly due to low parasite densities, although it can cause
severe anemia5 and nephrotic syndrome in both children and
adults.6,7 Plasmodium malariae is often found in coinfections
with other Plasmodium species,3 and because of this and the
focus on P. falciparum, its biology, prevalence, and specific
public health impact havemostly beenunderstudied.Previous
studies in areas of seasonal transmission, such as the Gam-
bia, have reported P. malariae to be responsible for about half
of the malaria episodes observed outside the transmission
season.8 The implications of this dynamics are poorly un-
derstood in terms of sustained transmission, acquisition of
antimalarial drug resistance, and malaria elimination.
Species-specific diagnosis of P. malariae is uncommon in
routine malaria diagnosis; rapid diagnostic tests (RDTs), the
most widely used diagnostic tools, predominantly target P.
falciparum, whereas other Plasmodium species are identified
as “pan-species.”9Asa result, its burdenand thepopulation at
risk in most endemic areas remain largely unknown. A recent
study reported persistent transmission of P. malariae over a
22-year period in Tanzania, suggesting that the decline in
P. falciparum prevalence could provide a favorable ecological
niche for other malaria parasite species.10 This has also re-
cently been reported for Plasmodium knowlesi, a zoonotic
malaria species, in Malaysia.11
There were an estimated 228 million cases of malaria
worldwide in 2018, 93% in Africa, with Nigeria contributing
approximately 25% of these.1 Malaria transmission in Nigeria
is perennial, mostly due to conducive geographic landscape,
high temperatures, and rainfall; about 85% of the population
lives in areas of mesoendemic transmission.12 Although
P. falciparum is the dominant species, responsible for more
than 95% of cases of clinical malaria, P. malariae is found in
9.8% of malaria cases, mostly as mixed infection.12 Never-
theless, its prevalence, mostly determined by molecular meth-
ods, can be as high as 26%.13 Here, we report the detection of
P. malariae infections from two sampling surveys aimed to
describe the molecular and seroprevalence of this malaria
parasite species in individuals attending health facilities in two
geopolitical and climatic zones of southern Nigeria.
METHODS
Study site and Plasmodium spp. survey. A first survey
was carried out between October and December 2017 to
compare P. malariae infections in two study sites in southern
Nigeria, Lagos (Ikorodu local government area) in the south-
west zone and Calabar, Cross River state (Akpabuyo local
government area) in the southeast zone (Figure 1A). Sus-
pected malaria cases sent for malaria test at the study health
facilities were screened using a pan-species RDT kit, SD
Bioline, Cat No 05FK60 (Abbott Diagnostics, Lake Forest, IL),
after providing written informed consent to participate in the
study. Blood sample was then collected from RDT-positive
individuals for thick blood film preparation for microscopy
and dried blood spots (DBSs) for molecular detection of
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Plasmodium species and serology assays. At the peak of the
following malaria transmission season (November/December
2018), a second survey was carried out in Calabar only be-
cause of the higher prevalence of P. malariae, expanding to
additional health facilities to increase catchment, and the total
numbers screened within the sample collection period
(Figure 1B). Following prior community sensitization, partici-
pants who reported at the study health facilities with sus-
pected malaria were recruited, and samples were collected
from consenting individuals as described in the first survey,
irrespective of their RDT results.
Lagos is the most populous city in Africa, with a population
of approximately 15 million people; it has a tropical savanna
climate, with a wet season between April and October, and a
dry season in the following months. The wettest month is
June, with mean precipitation of 315.5 mm (12.42 in). Located
near the equator, Lagos has minimal seasonal temperature
variation, with high temperatures ranging between 28.3Cand
32.9C.14 Calabar has a tropical monsoon climate, with a long
wet season (February–November) and a short dry season
covering the remaining 2 months. Temperatures are relatively
constant throughout the year, with average high temperatures
ranging between 25C and 28C; relative humidity is high with
most months of the year, recording a monthly mean value of
80%, and annual average precipitation more than 3,000 mm
(120 in).15,16
Ethical and sample size considerations. Ethical approval
was obtained from the respective authorities in Lagos and
Cross River state, references: IRB/17/038, CRSMOH/RP/
REC/2017/545, and CRSMOH/RP/REC/2017/809. Written
informed consent was obtained for adult participants, whereas
parental or guardian consent was obtained for minors. Par-
ticipants did not receive any compensation for their partici-
pation in study. All individuals diagnosedwithmalaria byRDTs
were treated accordingly, whereas febrile individuals with a
negative RDT result were referred to the health facility staff
for further investigation. A minimum of 500 samples per site
was required to be screened in each survey, assuming
maximum malaria prevalence of 50% in suspected cases
with 95% CI and 5% margin of error and an additional 30%
adjustment for possible incomplete data by any of the de-
tection methods.
Detection of Plasmodium spp. parasites. A pan-species
RDT kit (SD Bioline, Cat No 05FK60), which qualitatively and
differentially detects histidine-rich protein II antigen of P. fal-
ciparum and lactate dehydrogenase (pLDH) of Plasmodium
species in humanwhole blood,wasused formalaria screening
according to the manufacturers’ protocol. Any sample with
either P.f, pan, or both lines in addition to the control line was
considered positive. Thick blood microscopy slides stained
with 10% Giemsa solution were examined across 100 high-
power fields by two microscopists and parasite counts
recorded per number of white blood cells (WBCs) observed. In
case of ³ 20% variance in counts between primary and sec-
ondary microscopists, the counts closest to that of a third
reader were retained. A slide was declared negative only after
observing no parasite in 100 microscopic high-power fields,
whereas parasite density was calculated using WHO proto-
cols; the number of parasitized erythrocytes against 8,000
WBCs17 was expressed as parasitaemia/mL of blood.
For molecular diagnosis of Plasmodium spp., DNA was
extracted from DBS samples using the QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany) according to manufacturers’ pro-
tocols. For the preliminary survey, the presence ofPlasmodium
species was detected using a commercial species-specific
quantitative real-timePCR (qPCR) assay,Genesig®Plasmodium
species kits (Primerdesign™ Ltd., Chandler’s Ford, United
Kingdom) according to manufacturers’ protocol. Subsequently,
the presence ofP.malariae andPlasmodiumovalewasdetected
using a custom qPCR assay targeting the Plasmepsin gene,18
which showed comparable results with the Genesig kit (Primer-
design Ltd.), whereas the presence ofP. vivaxwas not assessed
further. Pre-amplification was performed using 0.1 μM of the
forward and reverse primers for P. malariae (CCWR2K1_Fwd
TTCAGTCAGGATATGTAAAACAAAATTATTTAGGTA; CCWR2




in a 15-μL reaction. Themain amplification reaction contained
FIGURE 1. Map of study sites in Nigeria showing (A) Lagos (southwest zone) andCrossRiver (south–south zone) states; and (B) health facilities in
Cross River state, where participants were recruited. This figure appears in color at www.ajtmh.org.
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3μL of pre-amplifiedproducts in a 15-μL total reaction volume
and was performed using 1× qPCR Taqman Universal Master
Mix (Thermo Fischer Scientific, Waltham, MA), 0.4 μM of the
forward and reverse primers, and 0.2 μM of the labeled probe
(P. malariae, CCWR2K1_Probe TCGTCTAGTTCTATTACGT-
CATTTTC and P. ovale, CCRR9V5_Probe TCAGTTGCTTCAA-
CAAATTT). Pre-amplificationwas performedunder the following
conditions: initial denaturation for 5minutes at 95C, 12 cycles of
denaturation for 30 seconds at 95C, annealing at 60C for 1
minute, and extension for 90 seconds at 72C, whereas main
amplification and detection were performed under the following
conditions: initial denaturation for 10 minutes at 95C, 40 cycles
of denaturation for 10 seconds at 95C, and data collection for 1
minute at 60C. Plasmodium falciparum was detected using a
highly sensitiveqPCRassay (varATSqPCR) targetingmulti-copy
subtelomeric sequences.19 Amplification reaction was per-
formed using 1× qPCR Taqman Universal Master Mix (Thermo
Fischer Scientific).
Peptide design and serology assays. Plasmodium
malariae–specific peptides were designed from highly immu-
nogenic epitopes of three P. malariae antigens—apical mem-
brane antigen (AMA1), circumsporozoite surface protein (CSP),
and lactose dehydrogenase (LDH) (Table 1). A P. falciparum–
specificpeptidewasalsodesigned fromthesameregionasone
of the P. malariae antigens – AMA1 (PmAMA1) peptides to ex-
plore species specificity. A web tool, SVMTriP (System Biology
Laboratory of Chi Zhang, University of Nebraska, Lincoln,
NE),20 was used to predict linear antigenic epitopes from the
whole P. malariae antigen sequences, and the peptides were
queried for species specificity using NCBI BLASTP 2.9.0+
(Bethesda, MD). The regions of immunogenic epitopes con-
taining the peptides were then compared with orthologs of
predicted P. falciparum epitopes available on the Plasmodium
database21 and the Immune Epitope Database and Resource
Analysis.22 The peptides indicating high species specificity and
high immunogenicity were chosen for synthesis (thinkpep-
tides®ProImmune Ltd.,Oxford,UnitedKingdom) at 95%purity
and 1–4 mg synthesis scale.
Antibodies against the Plasmodium spp. peptides were
detected by indirect ELISA on eluted filter paper samples. One
disc (6mm)per samplewaspunchedandplacedat thebottom
of 96-well plates—flat bottom with low evaporation lids
(Corning Inc., New York, NY). Serum from DBS was eluted
following overnight (18 hours) incubation at 4C in 150 μL of
reconstitution buffer (1× phosphate buffer saline; 0.2%
Tween20). The reconstituted solution was equivalent to a 1:
100 dilution of whole blood, corresponding to 1:200 dilution of
plasmaorserumantibodies, if thebloodwereat50%hematocrit.23
Peptides were coated on 96-well Nunc MaxiSorp™ Flat-Bottom
Plates (Thermo Fischer Scientific) at a concentration of 3 μg/mL.
Following blocking of all remaining binding surfaces with 1%
skimmedmilk, DBSeluatewas addedat a final concentration of 1:
2,000 with respect to the corresponding plasma sample and an-
alyzed in duplicate wells per sample. Each ELISA plate included a
positive control, which was a pool of DBS eluate from samples
confirmed to be P. malariae positive by microscopy and qPCR.
Also included in each plate were plate blanks (no serum) and
negative control, which was unexposed European pooled se-
rum.24 Secondary detection was with antibody peroxidase con-
jugated human IgG (H&L) (Sigma-Aldrich, Taufkirchen, Germany),
developed with Pierce™ TMB Substrate Kit (Thermo Fischer Sci-
entific). The reactionwas stopped using 50 μL of StopSolution for
TMB substrates (Thermo Fischer Scientific). Optical densities
(ODs) were read on the EMax® Plus microplate reader (Molecular
Devices, San Jose, CA) at 450 nm.
Data analysis. Data analysis was conducted using Micro-
soft Excel spreadsheet, GraphPad Prism version 8.4.2 (San
Diego, CA), and Stata IC 16 (Stata Corp., College Station, TX).
The prevalence of P. malariae and non-falciparum species
detected by the different detection methods was compared
from the different study sites. Analytical procedures for re-
ducing between-plate variation in the serology included cal-
culating the differences between the mean ODs averaged
across the duplicates of the pooled positive control for each
plate and the overall mean OD values across all plates, and
obtaining the estimated plate effect for a specific plate by
averaging the calculated differences across all pooled con-
trols. Test samples on a given plate were then adjusted by
subtracting the estimated plate effect from their OD values.25
Positivity for antimalarial peptide response was obtained by
modeling their normalized fold over the negative control (FOC)
values (log2 transformed), using finite mixture models, and
Gaussian distribution with two components.23,24 The esti-
mated mean of the narrower distribution was used as the
mean for negative samples. The cutoff for seropositivity was
obtained by taking the difference between the peptide FOC
values and the mean of the narrower distribution plus 2 SDs.
Seroprevalence rates were analyzed according to the follow-
ing age-groups: 10–20 years, 20–30 years, and > 30 years,
which corresponded with estimated the duration of exposure
to malaria. A three exponent nonlinear regression model and
line of best fit, using the quadratic estimation, was used to
obtain the predicted probability of being seropositive for a
particular peptide.
RESULTS
Summary of participants recruited. In 2017, a total of 243
(21.7%) individuals with a positive malaria RDT result were
recruited of 1,115 participants screened—520 screened from
Lagos and 595 from Calabar. Rapid diagnostic test positivity
rate in Lagos was 13.7% and 28.9% in Calabar (Figure 2A).
TABLE 1
List of Plasmodium spp. peptides for the serology assays
S/N Peptide name Peptide sequence Sequence location Antigen Parasite spp.
1 PmAMA1-1 VLRKRYEEHADLMNLNDLSL 141–160 AMA1 P.malariae
2 PmAMA1-2 VKLYSLDGEKIVLPRIFISN 405–424 AMA1 P.malariae
3 PmCSP AGNAAGNAAGNAAGNAAGNE 256–275 CSP P.malariae
4 PmLDH-1 ALIVAAHGNKMVPLKRYITV 176–169 LDH P.malariae
5 PmLDH-2 LGGVLDTSRLKYYISQKLNV 150–169 LDH P.malariae
6 PfAMA1 TLDEMRHFYKDNKYVKNLDE 194–213 AMA1 P. falciparum
AMA1 = apical membrane antigen; CSP = circumsporozoite surface protein; LDH = lactose dehydrogenase; P. falciparum = Plasmodium falciparum; P. malariae = Plasmodium malariae.
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Most of the RDT-positive cases were in Calabar (71%, 172/
243); children aged 6–10 years were the largest age-group
(36%, 88/243; Table 2). The following year, a total of 798
participants were recruited from four health facilities in Cala-
bar (77%, 613/798), mostly from two of the facilities (Table 2).
The age distribution of the participants was different from that of
the preliminary survey performed in 2017; adolescents and
adults represented about half of the participants (51%, 410/798),
followed by children aged 11–15 years (21%, 168/798; Table 2).
Molecular prevalence of Plasmodium species. In 2017,
when only RDT-positive individuals were recruited, the pro-
portion of Plasmodium species detected in Lagos by qPCR
was81.7%,1.4%, and1.4% forP. falciparum,P.malariae, and
P. ovale, respectively. In Calabar, the proportions detected
were 80.8%, 9.9%, and 5.8%, respectively (Figure 2B). No P.
vivax infection was detected in both locations. Similar pro-
portions (81.7% versus 73.2% [Lagos] and 80.5% versus
75.9% [Calabar]) of P. falciparum infections were detected by
qPCR and microscopy in the RDT-positive samples from the
different study areas. However, more P. malariae and P. ovale
infections were detected by qPCR, with higher proportions in
Calabar than in Lagos. This emphasized the low specificity
of species-specific identification of malaria parasites by mi-
croscopy. Table 3 summarizes the prevalence of Plasmodium
spp. detected as mixed or mono infections in the four health
facilities in Calabar. On average, relatively more non-falcipa-
rum species infections were detected in malaria samples
recruited from the two facilities situated to the north of
Akpabuyo local government area (26.5%) than those to the
south (18.7%); however, this was not statistically significant
(P = 0.062) (Figure 3). Despite observing a higher proportion
of P. malariae infections in older individuals (> 15 years), the
odds of having P.malariae as a mono-infection were highest
in the < 5 year age-group. The least odds formono-infections
were in those of ages 11–15 years (Table 4); the odds of
P. malariae mono infections were highest in Asabanka, with
FIGURE 2. Summary of diagnostic results. (A) Prevalence of malaria in both surveys by RDTs. (B) Proportion of Plasmodium species detected by
qPCRandmicroscopy inRDT-positive samples from the first survey.Mx_Pf=P. falciparumdetectedbymicroscopy;Mx_Pm=P.malariaedetectedby
microscopy; qPCR=quantitative real-timePCR; qPCR_Pf =P. falciparumdetected by qPCR; qPCR_Pm=P.malariaedetected by qPCR; qPCR_Po=
P. ovale detected by qPCR; qPCR_Pv = P. vivax detected by qPCR. RDT = rapid diagnostic test. This figure appears in color at www.ajtmh.org.
TABLE 2
Summary of participants recruited in the two malaria transmission seasons
First survey, n (%) Second survey, n (%)
Lagos Calabar Total Akansoko HF Asabanka HF Ifondo HF Nkakat Eyamba HF Total
Total 71 172 243 97 266 88 347 798
Gender
Male 31 (43.7) 88 (51.2) 119 (48.9) 45 (46.4) 120 (45.1) 38 (43.2) 147 (42.4) 350 (43.9)
Female 40 (56.3) 84 (48.8) 124 (51.0) 52 (53.6) 146 (54.8) 50 (56.8) 200 (57.6) 448 (56.1)
Age-group (years)
0–5 19 (26.7) 29 (16.8) 48 (19.7) 10 (10.3) 49 (18.4) 18 (20.5) 18 (5.2) 95 (11.9)
6–10 19 (26.7) 69 (40.1) 88 (36.2) 6 (6.2) 71 (26.7) 9 (10.2) 39 (11.2) 125 (15.6)
11–15 13 (18.3) 30 (17.4) 43 (17.6) 7 (7.2) 38 (14.3) 6 (6.8) 117 (33.7) 168 (21.1)
> 15 21 (29.5) 44 (25.5) 65 (26.7) 74 (76.3) 108 (40.6) 55 (62.5) 173 (49.8) 410 (51.4)
HF = health facility.
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4.5% mono-infection, and the least in Ifondo, with 1.1%
mono-infection (Tables 3 and 4).
Serological responses to the different P. malariae
peptides. Anti-peptide IgG antibody levels were detected
against each of the Plasmodium spp. peptides designed,
and these were relatively higher than the median values of
a pool of nonimmune sera, reported as FOC. More than
70% of the samples showed antibody reactivity levels
TABLE 3
Summary of non-falciparum species detected in south–south Nigeria as mixed and mono-infections by the different diagnostic methods—RDT,
microscopy, and qPCR
RDT Plasmodium falciparum, n (%) Pan-spp., n (%)
Plasmodium spp. Infection All spp., n (%) Pf_total Pf_mono Pan_total Pan_only
Akansoko (97) 31 (31.9) 26 (26.8) 14 (14.4) 17 (17.5) 5 (5.2)
Asabanka (266) 41 (15.4) 40 (15.0) 35 (13.2) 6 (2.3) 1 (0.4)
Ifondo (88) 21 (23.9) 21 (23.9) 17 (19.3) 4 (4.5) 0 (0)
Nkakat Eyamba (347) 93 (26.8) 90 (25.9) 88 (25.4) 5 (1.4) 3 (0.9)
P. malariae, n (%) Mixed infections, n (%)
Microscopy All spp., n (%) Pm_total Pm_mono Pf + Pm
Akansoko (97) 6 (6.2) 2 (2.1) 1 (1.0) 1 (1.0)
Asabanka (266) 33 (12.4) 6 (2.3) 5 (1.9) 1 (0.4)
Ifondo (88) 15 (17.1) 0 (0) 0 (0) 0 (0)
Nkakat Eyamba (347) 99 (28.5) 16 (4.6) 15 (4.3) 1 (0.3)
P. malariae, n (%) Plasmodium ovale, n (%) Mixed infections, n (%)
qPCR All spp., n (%) Pm_total Pm_mono Po_total Po_mono Pf + Pm Pf + Po Pm + Po Pf + Pm + Po
Akansoko (97) 25 (25.8) 6 (6.2) 2 (2.1) 2 (2.1) 1 (1.0) 3 (3.1) 0 (0) 1 (1.0) 0 (0)
Asabanka (266) 96 (36.1) 24 (9.0) 12 (4.5) 3 (1.1) 1 (0.4) 12 (4.5) 2 (0.8) 0 (0) 0 (0)
Ifondo (88) 65 (73.9) 10 (11.4) 1 (1.1) 3 (3.4) 0 (0) 8 (9.1) 2 (2.3) 0 (0) 1 (1.1)
Nkakat Eyamba (347) 224 (64.6) 42 (12.1) 9 (2.6) 10 (2.9) 2 (0.6) 32 (9.2) 7 (2.0) 0 (0) 1 (0.3)
Pf = P. falciparum; Pm = P. malariae; Po = P. ovale; qPCR = quantitative real-time PCR; RDT = rapid diagnostic test.
FIGURE 3. Proportion ofPlasmodium species detected in the four villages in southeasternNigeria, detectedbyquantitative real-timePCR (qPCR)
(qPCR_Pf = P. falciparum; qPCR_Pm = P. malariae; qPCR_Po = P. ovale). This figure appears in color at www.ajtmh.org.
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greater than the negative control for each of the peptides
(PmAMA1-1 = 73.1%, PmAMA1-2 = 86.7%, P. malariae
CSP [PmCSP] = 78.2%, P. malariae LDH [PmLDH-1] =
80.9%, PmLDH-2 = 87.2%, and PfAMA1 = 80.3%). From
the area under the receiver operator curve for the different
peptides, the FOC responses of all the peptides could
predict up to 70% of the results obtained by microscopy
(range = 62.6–70.5%) and RDTs (range = 66.4–71.9%)
(Figure 4). The P. malariae–specific anti-peptide antibody
reactivities relative to the P. falciparum peptide for sam-
ples from the first survey expressed significantly higher
P. malariae responses in Calabar than in Lagos with the
exception of the PmCSP peptide, to which Lagos samples
were more reactive (Supplemental Figure 1). Because of
the small number of samples from Lagos and some of the
health facilities in Calabar, all samples were subsequently
analyzed together, and the geographical location was
not considered. As observed with P. falciparum, sero-
prevalence increased with age for all the P. malariae
peptides from the age of 10 years (Figure 5). Proportions
of seropositivity in younger than 10-year age-groups
were variable between antigens, with no consistent
pattern between peptides (Supplemental Figure 2). The
proportion of seropositivity decreased for PmLDH-1,
whereas it increased for PfAMA1 for this younger age-
group.
DISCUSSION
The prevalence of non-falciparum species was relatively
heterogeneous in health facilities in the southwest and south–
south zones of Nigeria, supporting the need for broadening the
focus of the National Malaria Control Program beyond
P. falciparum.26–29 Nigeria accounts for an estimated 25% of
global malaria cases, mostly considered to be due to
P. falciparum infection.30 With the push for malaria eradica-
tion, this indicates that other human Plasmodium species
should also be considered in current elimination strategies
and evaluation of intervention outcomes. UnlikeP. falciparum,
P. malariae infections were more prevalent in individuals older
than 5 years. Current malaria intervention strategies such
as seasonal malaria chemoprevention (SMC) usually target
children aged 3–59 months. Hence, older age-groups in
P. malariae–endemic areas could serve as a reservoir for
future expansion of this parasite if P. falciparum is selec-
tively eliminated. Higher prevalence of P. malariae infec-
tions was also observed in older age-groups in Papua New
Guinea based on a sensitivemolecular diagnosticmethod,
post-PCR ligase detection reaction–fluorescent micro-
sphere assay, compared with light microscopy.31 Al-
though overall malaria parasite species differ, the rates for
P. malariae infections were comparable to those reported
for Papua, despite the wide geographic distance and
TABLE 4
Odds of P. malariae occurring as mono-infections or mixed infections with other Plasmodium spp. in the four different villages and across
age-groups
Mono infections Mixed infections Total Odds* 95% CI Odds ratio† 95% CI
Health facility
Akansoko 2 4 6 0.5 0.09–2.73 4.5 0.25–80.57
Asabanka 12 12 24 1.0 0.45–2.23 9 0.79–101.81
Ifondo 1 9 10 0.11 0.01–0.88 1 –
Nkakat Eyamba 9 33 42 0.27 0.13–0.57 2.46 0.26–22.82
Age-group (years)
0–5 4 3 7 1.33 0.29–5.96 16.67 1.39–199.42
6–10 3 9 12 0.33 0.09–1.23 4.17 0.55–31.75
11–15 2 25 27 0.08 0.02–0.34 1 –
> 15 15 21 36 0.71 0.37–1.39 8.93 1.58–50.32
P. malariae = Plasmodium malariae.
* Odds of P. malariae observed as a mono-infection compared with mixed infections.
†Odds ratio calculated relative to the least odds.
FIGURE 4. Area under the receiver operator curve (ROC) showing comparison of fold over the negative control for each of the peptideswith rapid
diagnostic test (RDT) and microscopy results. This figure appears in color at www.ajtmh.org.
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additional prevalence of P. vivax in Papua. A wider sur-
veillance and reporting of non-falciparummalaria parasite
species and broadening of future malaria elimination
strategies to include all population age-groups at risk of
infection with P. falciparum and non-falciparum species is
suggested. Identification of five cases of P. vivax and a
10.9% prevalence of P. malariae in a recent study of
southern Nigerian communities further corroborates our
findings and need for enlarged surveys.29
Despite the lower prevalence of infection in children < 5
years of age, the odds of P. malariae mono-infections were
higher in this age-group than in individuals aged > 15 years.
This could reflect the level of exposure and immunity, as
younger children may be protected by maternal antibodies as
well as interventions such as insecticide-treated bed nets and
SMC.32 The age distribution also mirrors the pattern seen for
P. falciparum, where an age shift in high infection rates to older
children hasbeen reported acrossAfrica following large scale-
up of malaria interventions.33 The odds of P. malariae mono-
infection also varied between health facilities, with lowest
infection odds in Ifondo, which had, by molecular methods,
the highest prevalence of P. falciparum infections. This,
however, would require further investigation because of the
small numbers reported here, reflected in the wide CIs.
Nonetheless, some studies have reported higherP.malariae
prevalence rates when outside the P. falciparum peak
transmission, suggesting an interaction between the oc-
currence of these species.34–36 Such dynamics could be
driven by co-immune mechanisms as the genomes and
proteins of these species are highly similar,37 hypothetically
allowing for high immune responses againstP. falciparum to
eliminate P. malariae from coinfections. There could also be
an ecological dynamics in which higher multiplication rates
and shorter cycle time of P. falciparum would displace P.
malariae, which often occurs at low parasite densities and
prefer to invade older red blood cells (RBCs).4 Infected RBCs
are cleared by the spleen during malaria infections,38,39 which
may in turn remove P. malariae from peripheral circulation.
However, P. malariae has been reported to persist following
treatment of mixed species malaria with artemisinin combi-
nation therapies,40–42 an indication that further studies are
needed to elucidate the dynamics and consequences of
malaria parasite coinfections. This will require specific sur-
veillance tools, including sensitive and specific diagnostic and
serological assays.
In the absence of whole antigen ELISA assays for
P. malariae and other non-falciparum infections, species-
specific peptide ELISA assays provided an alternative tool for
determining seroprevalence of antibodies againstP.malariae.
Predicted peptide epitopes from P. malariae AMA1, CSP, and
LDH proteins were all recognized by human IgG antibodies, ev-
idence of specific immune responses in exposed communities.
Higher relative antibodies were seen in the south–south zone
with highermalaria transmission. ThusP.malariae elicits specific
antibody responses, which could be targeted for the develop-
ment of sensitive surveillance tools. Seroprevalence has been
used as a surrogate for exposure, enabling the determination of
forceof infectionandage-specific immunity forP. falciparumand
P. vivax, in endemic regions.24,43–45 ELISA techniques for the
detection of antibodies have also been widely used for the di-
agnosis of infectious diseases and have been used in malaria
since the 1970s.46 Adequately powered studies to compare and
predict transmission intensity of P. malariae and other non-fal-
ciparum species across sSA would be useful for strategizing
toward control and elimination of all malaria parasite species.
The first survey carried out in 2017 showed a lower preva-
lence of non-falciparum species in Lagos than in Calabar. This
was not surprising as urbanization in Lagos metropolitan city,
with better housing and access to health services, will limit
malaria transmission despite similar vector populations.47 A
consistent pattern of increased urbanization coincident with
decreasingmalaria transmission and elimination over the past
FIGURE 5. Seroprevalence rates of the different species-specific peptides in different age-groups; the slope is the estimated change of rate over
age-group. This figure appears in color at www.ajtmh.org.
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century has been reported.48 Although this study was not
designed to determine the epidemiology of P. malariae, a
properly designed epidemiological study would be more in-
formative. The non-falciparum infections in the urban area
were submicroscopic and could only be detected by sensitive
molecular methods. This emphasizes the challenges to
malaria diagnosis with decreased prevalence and more sub-
microscopic infections. Sensitive and accessible diagnostic
tools for routine detection of all human Plasmodium species
therefore remain important. Microscopy, which is still con-
sidered the gold standard for malaria diagnosis, is laborious
and time consuming for Plasmodium speciation, requiring
expert microscopists. Current antigen-based pan-species
RDTs also present peculiar challenges, including low sensi-
tivity and lack of species specificity.49 The poor sensitivity for
pan-species Plasmodium detection was recently demon-
strated in an experimental human blood-stage model for
P. malariae infection, where RDTs targeting pan-genus LDH
enzyme (pLDH) remained negative despite the presence of
symptoms consistent with malaria 72-hour before testing.50
Most of the malaria infections detected by PCR were low-
grade infections or submicroscopic, which is a well-documented
limitation of microscopy, and this may explain the high dis-
crepancy between Plasmodium species detected by micros-
copy compared with PCR. As for P. falciparum, ultrasensitive
molecular diagnostics that target multi-copy genes will be
relevant to assess the true burden of non-falciparum malaria
infections.
Despite recent reports ofP. vivax detection in Duffy-negative
individuals in sSA, including southwesternNigeria,51 noP. vivax
infection was detected. The prevalence of P. vivax in Duffy-
negative individuals could therefore be specific to some sus-
ceptible populations driven by yet undetermined biological
and environmental factors.
In conclusion, the prevalence rates of non-falciparum spe-
cies reported here indicate that approaches for routine di-
agnosis in endemic settings should be encouraged to
ascertain the true burden of these species as well as for ap-
propriate interventions toward pan-species malaria elimina-
tion. Studies to determine the prevalence and dynamics of
non-falciparum species as well as associated risk factors in
endemic populations need to be expanded across sSA.
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